
Immunological veterinary medicinal products carry a control step that most other veterinary products do not. Under Article 128 of Regulation (EU) 2019/6, a Member State[…]

Some veterinary products will never justify a full development programme. The species is too small a market, the disease is rare or geographically confined, or[…]

Any veterinary medicinal product intended for food-producing animals has to clear a gate that does not exist in human medicine: the residue assessment. EU law[…]

Regulation (EU) 2019/4, adopted on 11 December 2018, governs the manufacture, placing on the market and use of medicated feed. It sits alongside Regulation (EU)[…]

The cascade is the legal derogation that allows a veterinarian to treat an animal when no authorised product fits. It is set out in Articles[…]

Commission Implementing Regulation (EU) 2022/1255 of 19 July 2022 designates antimicrobials and groups of antimicrobials that are reserved for the treatment of certain infections in[…]

Article 57 of Regulation (EU) 2019/6 requires Member States to collect data on the volume of sales and on the use of antimicrobial medicinal products[…]

Veterinary pharmacovigilance under Regulation (EU) 2019/6 is not a scaled-down version of the human system. It is built around continuous signal management rather than routine[…]

Regulation (EU) 2019/6 abandoned the familiar human-medicines variation categories and replaced them with a binary split: variations not requiring assessment, and variations requiring assessment. The[…]

Since 16 July 2026, good manufacturing practice for veterinary medicinal products has been set out in directly applicable EU law rather than in guidance. Commission[…]